BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

3:58 PM
Sep 21, 2012
 |  BC Extra  |  Clinical News

Astex discontinues amuvatinib development

Astex Pharmaceuticals Inc. (NASDAQ:ASTX) discontinued development of amuvatinib after data from 21 evaluable small cell lung cancer (SCLC) patients in stage one of the Phase II ESCAPE trial showed that the product missed the pre-specified stage one primary...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >